These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
798 related articles for article (PubMed ID: 25617253)
1. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study. Savitz A; Lane R; Nuamah I; Singh J; Hough D; Gopal S J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669 [TBL] [Abstract][Full Text] [Related]
3. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949 [TBL] [Abstract][Full Text] [Related]
4. A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine. Kotler M; Dilbaz N; Rosa F; Paterakis P; Milanova V; Smulevich AB; Lahaye M; Schreiner A J Psychiatr Pract; 2016 Jan; 22(1):9-21. PubMed ID: 26813484 [TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. Levitan B; Markowitz M; Turkoz I; Fu DJ; Gopal S; Alphs L Int Clin Psychopharmacol; 2016 Nov; 31(6):315-22. PubMed ID: 27434314 [TBL] [Abstract][Full Text] [Related]
6. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241 [TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study. Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Li H; Rui Q; Ning X; Xu H; Gu N Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. Canuso CM; Turkoz I; Sheehan JJ; Bossie CA J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963 [TBL] [Abstract][Full Text] [Related]
14. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691 [TBL] [Abstract][Full Text] [Related]
15. Paliperidone extended release: a review of its use in the management of schizophrenia. Chwieduk CM; Keating GM Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835 [TBL] [Abstract][Full Text] [Related]
16. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Zhang Y; Dai G Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study. Gopal S; Lane R; Nuamah I; Copenhaver M; Singh J; Hough D; Bach M; Savitz A CNS Drugs; 2017 Sep; 31(9):797-808. PubMed ID: 28660406 [TBL] [Abstract][Full Text] [Related]
19. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484 [TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]